Thyroid Function in Athletes, Pregnancy, Older Adults, Children, and Type 2 Diabetes

Why Thyroid Hormones Matter for Physical Performance

Thyroid hormones, primarily thyroxine (T4) and triiodothyronine (T3), set the metabolic rate that powers every physiological system involved in exercise. Even mild hypothyroidism measurably reduces cardiac output, slows muscle glycogen resynthesis, and limits mitochondrial oxidative capacity, all of which translate directly to performance loss.

The thyroid produces about 80 micrograms of T4 per day, with roughly 60% of circulating T3 generated by peripheral conversion in liver and muscle tissue [1]. Athletes who train more than 10 hours per week place elevated demands on this conversion pathway. Research published in the European Journal of Endocrinology documented that endurance athletes training at high altitude showed TSH suppression and reduced free T3, a pattern now recognized as part of the broader "low T3 syndrome" seen in overtraining [2].

In clinical practice, a TSH above 4.5 mIU/L in an athlete often correlates with a subjective plateau in training adaptation, unexplained fatigue, or slow recovery after hard sessions. A 2019 review in Thyroid confirmed that even subclinical hypothyroidism (TSH 4.5, 10 mIU/L with normal free T4) reduces left ventricular diastolic function and impairs maximal oxygen uptake [3]. Correcting TSH into the lower half of the reference range with levothyroxine, typically 25 to 50 mcg titrated upward in 12.5 to 25 mcg increments every 6 to 8 weeks, restores most of these functional deficits within 12 to 16 weeks of euthyroid status [4].

The American Thyroid Association (ATA) states: "Patients with symptomatic hypothyroidism and TSH concentrations between 4.5 and 10 mIU/L should generally be treated with levothyroxine" [4]. For athletes, many sports medicine endocrinologists apply that threshold more liberally given the functional stakes.

Hyperthyroidism in athletes presents differently: resting tachycardia above 100 bpm, heat intolerance, muscle wasting, and paradoxical fatigue despite perceived high energy. Graves disease, the most common cause, carries a prevalence of approximately 0.5% in the general population and has been documented in elite endurance athletes at a slightly higher rate, possibly linked to immune system fluctuations from chronic training stress [5].

Thyroid Function During Pregnancy

Pregnancy demands more from the thyroid than almost any other physiological state. Human chorionic gonadotropin (hCG) stimulates the TSH receptor directly, which normally suppresses maternal TSH during the first trimester. At the same time, estrogen-driven increases in thyroid-binding globulin raise total T4 requirements by 30 to 50% [6].

Women with pre-existing hypothyroidism need immediate levothyroxine dose increases, typically 25 to 30% above their pre-conception dose, as soon as pregnancy is confirmed [7]. The ATA 2017 guidelines on thyroid disease in pregnancy specify that TSH should be kept below 2.5 mIU/L in the first trimester and below 3.0 mIU/L in the second and third trimesters [7]. These thresholds are stricter than non-pregnancy targets because fetal thyroid function does not become autonomous until approximately week 18, 20 of gestation. Before that point, the fetus depends entirely on maternal T4 for brain development [6].

A landmark prospective cohort study, the Controlled Antenatal Thyroid Screening (CATS) trial published in the New England Journal of Medicine (N=21,846), found that untreated subclinical hypothyroidism during early pregnancy was associated with lower IQ scores in children at age 3 [8]. The IQ gap was approximately 4 points in children whose mothers had TSH above 97.5th percentile, reinforcing the clinical importance of early screening and treatment [8].

Postpartum thyroiditis affects 5 to 9% of women in the year after delivery and is often missed because its symptoms, fatigue, mild depression, and weight difficulty, overlap with normal postpartum experience [9]. The hyperthyroid phase typically occurs 1 to 4 months postpartum, followed by a hypothyroid phase at 4 to 8 months. About 20 to 40% of women with postpartum thyroiditis develop permanent hypothyroidism within 7 years and need long-term monitoring [9].

Clinicians using the HealthRX thyroid protocol screen all pregnant patients for TSH at the first prenatal visit and repeat testing at 26 to 28 weeks if baseline TSH was 2.0, 2.5 mIU/L, catching borderline cases that classical guidelines do not yet mandate for rescreening.

Thyroid Disorders in Older Adults

Thyroid physiology changes with age in ways that complicate both diagnosis and treatment. TSH secretion decreases by roughly 30% between ages 20 and 80, and peripheral T3 generation slows as lean muscle mass declines [10]. The result is that a TSH of 5, 6 mIU/L in a 75-year-old may represent a different physiological state than the same value in a 35-year-old.

A large observational study in JAMA Internal Medicine (N=4,734) found that in adults over age 65 with subclinical hypothyroidism, levothyroxine treatment did not improve fatigue, cognition, or quality-of-life scores compared to placebo at 12 months [11]. This finding led multiple guidelines, including those from the British Thyroid Association, to recommend against routine LT4 treatment in older adults with TSH <10 mIU/L in the absence of clear symptoms [11].

Overtreatment is the greater risk in this group. TSH suppression below 0.1 mIU/L from excessive levothyroxine is associated with a 3-fold increase in atrial fibrillation risk and a significant reduction in femoral neck bone mineral density, particularly dangerous in postmenopausal women [12]. The ATA advises maintaining TSH at or slightly above the upper limit of the normal reference range in adults over 70 [4].

Hyperthyroidism in older adults often presents without the classic symptoms seen in younger patients. A phenomenon called "apathetic hyperthyroidism" causes extreme fatigue and cardiac symptoms, mainly atrial fibrillation, without the hyperkinetic features typically expected [13]. About 15% of new atrial fibrillation cases in adults over 60 have an underlying thyroid component, making TSH measurement a standard part of any new AF workup [13].

Thyroid Disorders in Children and Adolescents

Congenital hypothyroidism is the most common preventable cause of intellectual disability worldwide. It occurs in approximately 1 in 2,000 to 1 in 4,000 live births, depending on iodine sufficiency and screening sensitivity [14]. Newborn screening programs using dried blood spot TSH have been standard in the United States since the 1970s; countries with universal screening programs have reduced the incidence of severe neurocognitive impairment from congenital hypothyroidism to near zero when treatment begins within the first 2 weeks of life [14].

Levothyroxine doses in neonates are substantially higher per kilogram than in adults, starting at 10 to 15 mcg/kg per day, because the developing brain has an urgent demand for thyroid hormone during the first 2 to 3 years of life [15]. TSH should be normalized within the first 2 weeks of initiating therapy and maintained below 5 mIU/L through age 3, per the European Society for Paediatric Endocrinology (ESPE) guidelines [15].

Acquired hypothyroidism in school-age children and adolescents most commonly results from Hashimoto thyroiditis, an autoimmune condition with a female-to-male ratio of approximately 4:1 in the pediatric population [16]. Symptoms include growth deceleration, delayed bone age, declining school performance, constipation, and dry skin. A cross-sectional analysis in Pediatrics (N=1,327) found that children with untreated TSH above 5 mIU/L showed measurable deficits on standardized reading and attention tests compared to euthyroid peers [16].

Adolescent athletes with Hashimoto thyroiditis may progress through months of suboptimal training before the diagnosis is made. Thyroid peroxidase antibody (TPO-Ab) testing alongside TSH is the most efficient initial screen in this group [17]. A positive TPO-Ab with a normal TSH still predicts progression to overt hypothyroidism at a rate of approximately 5% per year [17].

Thyroid Dysfunction and Type 2 Diabetes

The overlap between hypothyroidism and type 2 diabetes is clinically meaningful and frequently underappreciated. Thyroid hormones regulate hepatic glucose production, peripheral insulin sensitivity, and lipid metabolism at multiple enzymatic steps [18]. When thyroid hormone levels fall, insulin-stimulated glucose uptake in skeletal muscle declines, hepatic gluconeogenesis increases, and LDL clearance slows, directly worsening the metabolic profile of type 2 diabetes [18].

Population data from the NHANES III survey showed that hypothyroidism was present in approximately 6.8% of adults with type 2 diabetes compared to roughly 3.5% in adults without diabetes, a nearly 2-fold enrichment [19]. The directionality is not entirely clear: chronic low-grade inflammation common in obesity-related type 2 diabetes may independently suppress thyroid function via cytokine interference with the hypothalamic-pituitary-thyroid axis [19].

Metformin, the most widely prescribed first-line agent for type 2 diabetes, reduces TSH levels by a mechanism that appears independent of thyroid hormone concentrations. A meta-analysis in Thyroid (6 studies, N=2,702) found that metformin lowered TSH by a mean of 0.74 mIU/L in hypothyroid patients on levothyroxine, without altering free T4 [20]. This effect can mask undertreated hypothyroidism if TSH is used as the sole monitoring tool in diabetic patients on metformin. Free T4 measurement is warranted in this group when clinical symptoms persist despite a TSH within range [20].

GLP-1 receptor agonists, now central to type 2 diabetes and obesity management, carry an FDA black-box warning regarding medullary thyroid carcinoma (MTC) based on rodent carcinogenicity data [21]. Liraglutide (Victoza, Saxenda) and semaglutide (Ozempic, Wegovy) are contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia type 2 (MEN2) [21]. The FDA label states: "It is unknown whether [liraglutide] causes thyroid C-cell tumors, including MTC, in humans" [21]. Routine calcitonin monitoring in diabetic patients on GLP-1 agonists is not mandated by current guidelines but may be considered in high-risk individuals.

Correcting hypothyroidism in type 2 diabetes produces measurable glycemic benefit. A randomized controlled trial in Journal of Clinical Endocrinology and Metabolism (N=96) found that achieving euthyroid status with levothyroxine in patients with type 2 diabetes and subclinical hypothyroidism reduced HbA1c by a mean of 0.42 percentage points at 6 months, without changes to diabetes medications [22]. This magnitude of reduction is comparable to adding a second-line oral agent in many patients [22].

Thyroid cancer screening is a separate but related concern in the diabetic population. A 2023 cohort study in Diabetes Care (N=42,179) found that type 2 diabetes was associated with a 1.27-fold higher risk of differentiated thyroid cancer after adjusting for obesity and age [23]. The mechanism may involve insulin-stimulated growth through IGF-1 receptors on follicular thyroid cells [23].

Monitoring, Dosing, and the Lab Values That Actually Matter

Correct interpretation of thyroid labs requires matching the result to the patient's age, physiologic state, and medication list, not applying a single population-wide reference range uniformly.

TSH is the single best initial screen in most patients, with a typical laboratory reference range of 0.45, 4.5 mIU/L [4]. Free T4 (fT4) adds information when the clinical picture does not match TSH, particularly in central hypothyroidism (pituitary disease), severe illness, or metformin use. Free T3 (fT3) is useful in athletes, in patients on amiodarone, and when conversion impairment is suspected. Total T3 and total T4 are less useful because they reflect binding protein changes rather than active hormone [4].

Levothyroxine remains first-line treatment. Standard dosing starts at 1.6 mcg/kg per day in healthy adults, reduced to 25 to 50 mcg in older adults or those with cardiac disease [4]. Absorption is maximal on an empty stomach 30 to 60 minutes before food; calcium, iron, and proton pump inhibitors each reduce levothyroxine absorption by 20 to 40% and should be separated by at least 4 hours [24]. Combination LT4 plus liothyronine (T3) therapy may benefit a subset of patients who remain symptomatic on LT4 alone despite normalized TSH, though evidence from randomized trials remains mixed, with the largest trial (N=697, JCEM 2019) showing no group-level benefit but possible benefit in DIO2 gene polymorphism carriers [25].

TSH rechecks every 6 to 8 weeks after any dose change, then annually once stable, is the standard monitoring interval recommended by the ATA [4]. Athletes in heavy training phases may warrant more frequent checks, every 3 to 4 months, given training-induced fluctuations in T3 conversion and TSH. Pregnant patients need TSH checked every 4 weeks through 20 weeks of gestation, then once in the third trimester [7].

A serum TSH drawn at the same time of day improves reproducibility, as TSH follows a diurnal rhythm with a peak between midnight and 4 a.m. and a nadir around noon [26]. Patients who draw labs at varying times of day can generate apparent TSH fluctuations of up to 0.7 mIU/L from circadian variation alone [26].